.png)
.png)
Rinri Therapeutics announces new Chair as it approaches first clinical trial
Sheffield, UK, 29 April 2024 - Rinri Therapeutics, a leader in regenerative cell therapies for sensorineural hearing loss, is pleased to announce the appointment of David Hipkiss as its new Independent Chair. This strategic move comes at a pivotal time as the company prepares to initiate first-in-human trials for its lead asset, Rincell-1.
David brings to Rinri Therapeutics over thirty years of experience in the biotech industry, where he has played key roles in the foundation, financing, and sale of several innovative life sciences companies. His previous leadership positions include CEO and Co-Founder at both Prosonix and Enesi Pharma, and he is presently Executive Chair at AlveoGene. His extensive experience in business development and fundraising in both private and public company settings will greatly benefit Rinri as it enters a critical phase of growth and development.
Utilising its proprietary OSPREY™ platform, Rinri Therapeutics is developing a portfolio of off-the-shelf regenerative cell therapy products designed to address sensorineural hearing loss, a significant global medical challenge. The company’s lead asset, Rincell-1, is designed to address neural hearing loss by regenerating auditory neurons and provide a novel treatment for patients with severe-to-profound age-related hearing loss or auditory neuropathy. Having achieved outstanding preclinical safety and efficacy data, Rincell-1 is progressing through CTA enabling studies to enable first-in-human trials in 2025.
Commenting on this, David said, “Hearing loss represents a substantial and growing health challenge where no therapeutic treatments exist. I am excited by the opportunity to join Rinri Therapeutics at this critical juncture and am inspired by the potential of our cutting-edge cell therapies to significantly impact this underserved medical need.”
Simon Chandler, CEO of Rinri Therapeutics, said, “Alongside our investors Boehringer Ingelheim Venture Fund, UCB Ventures and Pioneer Group, I’m delighted to welcome David as our new Chair. His guidance will be invaluable as we work towards our first clinical proof of concept data with Rincell-1. The Board would like to thank Nick Higgins, the former Chair, for his service and wish him well in his future endeavours.”
David brings to Rinri Therapeutics over thirty years of experience in the biotech industry, where he has played key roles in the foundation, financing, and sale of several innovative life sciences companies. His previous leadership positions include CEO and Co-Founder at both Prosonix and Enesi Pharma, and he is presently Executive Chair at AlveoGene. His extensive experience in business development and fundraising in both private and public company settings will greatly benefit Rinri as it enters a critical phase of growth and development.
Utilising its proprietary OSPREY™ platform, Rinri Therapeutics is developing a portfolio of off-the-shelf regenerative cell therapy products designed to address sensorineural hearing loss, a significant global medical challenge. The company’s lead asset, Rincell-1, is designed to address neural hearing loss by regenerating auditory neurons and provide a novel treatment for patients with severe-to-profound age-related hearing loss or auditory neuropathy. Having achieved outstanding preclinical safety and efficacy data, Rincell-1 is progressing through CTA enabling studies to enable first-in-human trials in 2025.
Commenting on this, David said, “Hearing loss represents a substantial and growing health challenge where no therapeutic treatments exist. I am excited by the opportunity to join Rinri Therapeutics at this critical juncture and am inspired by the potential of our cutting-edge cell therapies to significantly impact this underserved medical need.”
Simon Chandler, CEO of Rinri Therapeutics, said, “Alongside our investors Boehringer Ingelheim Venture Fund, UCB Ventures and Pioneer Group, I’m delighted to welcome David as our new Chair. His guidance will be invaluable as we work towards our first clinical proof of concept data with Rincell-1. The Board would like to thank Nick Higgins, the former Chair, for his service and wish him well in his future endeavours.”